Echo IQ Ltd (ASX: EIQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Echo IQ Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$310.55 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
653.79 million
Earnings per share
-0.023
Dividend per share
N/A
Year To Date Return
75.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Echo IQ Ltd (ASX: EIQ)
Latest News
Healthcare Shares
This biotech has lodged a key submission with US regulators
Share Gainers
Guess which ASX biotech stock just rocketed 25% on big US news
EIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Echo IQ Ltd
EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. It develops and patents algorithm dealing in Prescriptive Analytics. The company was founded by Richard Charles Anstey on March 31, 2010 and is headquartered in Sydney, Australia.
EIQ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Feb 2026 | $0.48 | $0.01 | 2.15% | 1,539,774 | $0.46 | $0.48 | $0.45 |
| 09 Feb 2026 | $0.47 | $0.01 | 2.20% | 2,129,810 | $0.44 | $0.47 | $0.43 |
| 06 Feb 2026 | $0.46 | $-0.02 | -4.17% | 3,186,257 | $0.48 | $0.48 | $0.45 |
| 05 Feb 2026 | $0.48 | $-0.02 | -4.00% | 1,570,093 | $0.50 | $0.50 | $0.46 |
| 04 Feb 2026 | $0.50 | $0.01 | 2.02% | 2,797,905 | $0.50 | $0.52 | $0.46 |
| 03 Feb 2026 | $0.50 | $0.01 | 2.04% | 1,608,525 | $0.48 | $0.52 | $0.48 |
| 02 Feb 2026 | $0.49 | $-0.01 | -2.02% | 1,461,898 | $0.50 | $0.50 | $0.47 |
| 30 Jan 2026 | $0.50 | $0.01 | 2.04% | 2,142,521 | $0.49 | $0.52 | $0.48 |
| 29 Jan 2026 | $0.49 | $-0.02 | -3.96% | 6,460,787 | $0.50 | $0.51 | $0.40 |
| 28 Jan 2026 | $0.51 | $-0.05 | -9.09% | 3,062,806 | $0.55 | $0.55 | $0.50 |
| 27 Jan 2026 | $0.55 | $0.03 | 5.77% | 5,933,944 | $0.54 | $0.57 | $0.50 |
| 23 Jan 2026 | $0.52 | $0.05 | 10.64% | 9,084,648 | $0.47 | $0.52 | $0.46 |
| 22 Jan 2026 | $0.47 | $0.06 | 14.81% | 8,685,509 | $0.41 | $0.49 | $0.41 |
| 21 Jan 2026 | $0.41 | $0.03 | 7.89% | 4,032,973 | $0.38 | $0.42 | $0.37 |
| 20 Jan 2026 | $0.38 | $0.00 | 0.00% | 1,586,840 | $0.38 | $0.39 | $0.37 |
| 19 Jan 2026 | $0.38 | $0.03 | 8.57% | 5,058,177 | $0.36 | $0.39 | $0.36 |
| 16 Jan 2026 | $0.35 | $0.01 | 2.90% | 2,443,824 | $0.35 | $0.36 | $0.34 |
| 15 Jan 2026 | $0.35 | $0.02 | 6.15% | 5,107,996 | $0.33 | $0.35 | $0.33 |
| 14 Jan 2026 | $0.33 | $-0.01 | -3.03% | 3,538,955 | $0.33 | $0.34 | $0.32 |
| 13 Jan 2026 | $0.33 | $0.02 | 6.45% | 3,294,000 | $0.32 | $0.33 | $0.32 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 30 Jan 2026 | Steven Formica | Exercise | 625,000 | $309,375 |
Conversion of securities. 3,750,000 Performance Rights
|
| 30 Jan 2026 | Steven Formica | Issued | 625,000 | $309,375 |
Conversion of securities.
|
| 30 Jan 2026 | Andrew Grover | Exercise | 1,000,000 | $495,000 |
Conversion of securities. 6,000,000 Performance Rights
|
| 30 Jan 2026 | Andrew Grover | Issued | 1,000,000 | $495,000 |
Conversion of securities.
|
| 31 Dec 2025 | Steven Formica | Expiry | 625,000 | $162,500 |
As advised by the company. 4,375,000 Performance Rights, Lapsed
|
| 31 Dec 2025 | Andrew Grover | Expiry | 1,000,000 | $260,000 |
As advised by the company. 7,000,000 Performance Rights, lapsed
|
| 08 Dec 2025 | Andrew Grover | Expiry | 4,850,000 | $1,212,500 |
Options expired. As per announcement on 09-12-2025
|
| 08 Dec 2025 | Stephen (Steve) Picton | Expiry | 2,000,000 | $500,000 |
Options expired.
|
| 08 Dec 2025 | Steven Formica | Expiry | 1,650,000 | $412,500 |
Options expired.
|
| 09 Oct 2025 | Stephen (Steve) Picton | Buy | 1,250,000 | $227,757 |
On-market trade.
|
| 08 Aug 2025 | Steven Formica | Issued | 3,000,000 | $615,000 |
Issue of options.
|
| 08 Aug 2025 | Steven Formica | Issued | 5,000,000 | $1,025,000 |
As advised by the company. estimated valuations, 5,000,000 Performance Rights
|
| 04 Mar 2025 | Ken Nelson | Issued | 4,000,000 | $40 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Stephen (Steve) Picton | Non-Executive Director | Oct 2021 |
Mr Picton has 35 years' experience in the technology industry having held senior positions in British Telecom (BT) and AAPT prior to him forming gotalk and relaunching LBNCo.
|
| Mr Steven Allen Formica | Non-Executive Director | Jul 2018 |
Mr Formica has management and business development experience. He has been businessman and operations manager for 31 years in several privately held business ventures including manufacturing, construction, landscape contracting, property development and integrated wholesale and retail businesses. More recently he has been a investor and non-executive director in mineral resource companies.
|
| Mr Andrew Grover | Executive ChairmanExecutive Director | May 2019 |
Mr Grover has 26 years' experience in management, business development, sales & marketing, administration and technology across a diverse range of industries. As a founder and investor in numerous innovative companies, his businesses have been featured in BRW Fast 100 and Deloitte's Fast 50 over several years. He was also CEO of an executive recruitment agency which was acquired by an ASX listed company.
|
| Mr Ken Nelson | Non-Executive Director | Dec 2024 |
Mr Nelson is a leading US-based medical technology and healthcare executive with 20 years' industry experience. During his career he has been pivotal in leading commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org), medical technology and digital health startup accelerator globally.
|
| Ms Jessamyn Sarah Lyons | Company Secretary | Oct 2021 |
-
|
| Mr Dustin Haines | Chief Executive Officer | Jan 2025 |
-
|
| Dustin Haines | Chief Executive Officer |
-
|
|
| Jessamyn Sarah Lyons | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 36,102,203 | 5.57% |
| A22 Pty Ltd | 28,500,000 | 4.40% |
| Stevsand Investments Pty Ltd <Steven Formica Family A/C> | 27,100,000 | 4.18% |
| Citicorp Nominees Pty Limited | 26,992,235 | 4.17% |
| Mr Brian Joseph Glynn | 13,200,000 | 2.04% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 11,865,173 | 1.83% |
| Heath Nominees (Aust) Pty Ltd <The Heath Family A/C> | 10,518,423 | 1.62% |
| Shah Nominees Pty Ltd | 8,700,000 | 1.34% |
| Ms Laura Bailey | 8,250,000 | 1.27% |
| Bellcoo Investments Pty Ltd <The Northlake S/F A/C> | 8,200,000 | 1.27% |
| Jpw Holdings Pty Ltd <Jpw Family A/C> | 8,194,635 | 1.27% |
| Kli Pty Ltd <The T Teh'S Family A/C> | 7,600,000 | 1.17% |
| Non Correlated Capital Pty Ltd <Investius Pb Micro Cap A/C> | 7,400,000 | 1.14% |
| Shah Nominees Pty Ltd <Louis Carsten Super Fund A/C> | 7,000,000 | 1.08% |
| Brazil Farming Pty Ltd | 6,738,037 | 1.04% |
| Awj Family Pty Ltd <A W Johnson Family A/C> | 6,540,000 | 1.01% |
| Alerte Ecg Pty Ltd | 6,151,517 | 0.95% |
| Colin Street Investments Pty Ltd | 5,727,273 | 0.88% |
| First One Realty Pty Ltd | 5,546,656 | 0.86% |
| Jpw Holdings Pty Ltd <J P W Family A/C> | 5,381,045 | 0.83% |
